B+
Bull case
25%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-06-25 · RankAlpha Sentiment Codex
XGN
ExagenFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bullish read is that Exagen is showing a real commercial-improvement pattern: Q1 2026 delivered record revenue, 12% year-over-year growth, 10% AVISE CTD volume growth, higher ASP, and better adjusted EBITDA, while full-year guidance was maintained. That combination supports a cautious rerating case if Q2 confirms the gains are repeatable.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Failure to sustain AVISE CTD volume and ASP gains could quickly pressure the current improvement narrative.
Momentum
98
Value
41
Sentiment
28
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.75 · Bull $7.50 · Bear $3.20Analysis 2026-06-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $10.57
Why
Momentum98 · Δ7d +0.4
Value41 · Δ7d -0.1
Sentiment28 · Δ7d +4.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • Failure to sustain AVISE CTD volume and ASP gains could quickly pressure the current improvement narrative.
- • Low sell-side coverage and loose peer comparability reduce external validation and can increase volatility around each quarterly update.
- • The bearish read is that Exagen still remains loss-making, liquidity is limited for a small-cap healthcare name, and the stock may need multiple more quarters of clean execution before investors fully trust the path to cash-flow positivity.
Catalyst clock
2026-06-30
Thin post-earnings revision support could help sentiment, but coverage is sparse
Lead driver: Value · See fundamentals
Momentum
98
8% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+0.0
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
28
45% active weight
Current posture
7d trendImproving
Δ7d
+4.4
Δ21d
+5.3
Why this grade
Composite grade F. Momentum 97.8 / Value 40.6 / Sentiment 28.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-25. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$5.75
Analysis reference price unavailable
Analysis 2026-06-25 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$3.20
Analysis reference price unavailable
Analysis 2026-06-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$176.12M
Beta
1.91
Shares Out
24.23M
P/E (TTM) · Derived
-7.9
P/S (TTM)
2.12
P/FCF (TTM) · Derived
-22.93
Rev YoY
+15.9%
EPS YoY
-37.1%
Gross Margin
+58.6%
Op Margin
-18.6%
Net Debt
-$4.55M
Current Ratio
3.18
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data